



Impact

By prioritising patients' quality of life and well-being, BRAINTEASER is transforming clinical care supporting the ability of public health systems to better predict, identify, and manage the risk factors that lead to amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), as well as their complications and outcomes.

The project benefits professionals, patients, and caregivers by offering them tools to support creating a brighter personal, social, and economic future.

Patients and caregivers:

Gain more control over health decisions:




ALS or MS patients can receive better predictions about their condition:



Health professionals and healthcare systems:

Benefit from improved resource planning in clinical practice and across the healthcare system:





Research and scientific teams:

Profit from BRAINTEASER's efforts to shape a regulatory framework for digital tools and methods:



Leverage cutting-edge technology and data insights through the European Open Science Cloud:





Results



Brainteaser

**Bringing Artificial Intelligence home for a better care of
amyotrophic lateral sclerosis and multiple sclerosis**



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the grant agreement No GA101017598. The European Commission's support for this project and the production of this website does not constitute an endorsement of the contents, which reflect the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein

info-brainteaser@lst.tfo.upm.es



[Privacy Policy](#) | [Cookies](#)

By [incognita](#)

[Manage consent](#)